These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39378786)

  • 1. High-throughput screening identified pacritinib as a promising therapeutic approach to overcome lenvatinib resistance in hepatocellular carcinoma by targeting IRAK1.
    Li C; Chen X; Wu J; Heng S; Xu Z; Gu H; Lin E; Wang J; Shan Y
    Biochem Biophys Res Commun; 2024 Nov; 734():150782. PubMed ID: 39378786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K/AKT/p53 signaling axis.
    Liu X; Gao X; Yang Y; Yang D; Guo Q; Li L; Liu S; Cong W; Lu S; Hou L; Wang B; Li N
    Apoptosis; 2024 Aug; 29(7-8):1161-1184. PubMed ID: 38743191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.
    Hu Q; Hu X; Zhang L; Zhao Y; Li L
    Med Oncol; 2021 Mar; 38(4):41. PubMed ID: 33730237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
    Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
    Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.
    Shi T; Iwama H; Fujita K; Kobara H; Nishiyama N; Fujihara S; Goda Y; Yoneyama H; Morishita A; Tani J; Yamada M; Nakahara M; Takuma K; Masaki T
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
    Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
    Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
    Kawamura Y; Saijo K; Imai H; Ishioka C
    Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.
    Hao J; Peng Q; Wang K; Yu G; Pan Y; Du X; Hu N; Zhang X; Qin Y; Li H
    Biomed Res Int; 2021; 2021():6613439. PubMed ID: 34337035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
    Hamaya S; Fujihara S; Iwama H; Fujita K; Shi T; Nakabayashi R; Mizuo T; Takuma K; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Morishita A; Kobara H; Ono M; Himoto T; Masaki T
    Anticancer Res; 2022 Mar; 42(3):1263-1275. PubMed ID: 35220216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma.
    Liu L; Liu S; Deng P; Liang Y; Xiao R; Tang LQ; Chen J; Chen QY; Guan P; Yan SM; Huang X; Hong JH; Chen J; Sun Y; Teh BT; Yu Q; Mai HQ; Tan J
    Cancer Res; 2021 Mar; 81(5):1413-1425. PubMed ID: 33402387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib.
    Zheng Y; Huang C; Lu L; Yu K; Zhao J; Chen M; Liu L; Sun Q; Lin Z; Zheng J; Chen J; Zhang J
    J Hematol Oncol; 2021 Jan; 14(1):16. PubMed ID: 33446239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
    Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
    J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines
    Ogasawara S; Mihara Y; Kondo R; Kusano H; Akiba J; Yano H
    Anticancer Res; 2019 Nov; 39(11):5973-5982. PubMed ID: 31704822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual effects of targeting neuropilin-1 in lenvatinib-resistant hepatocellular carcinoma: inhibition of tumor growth and angiogenesis.
    Ao J; Qiang N; Kanzaki H; Nakamura M; Kakiuchi R; Zhang J; Kojima R; Koroki K; Inoue M; Kanogawa N; Nakagawa R; Kondo T; Ogasawara S; Nakamoto S; Muroyama R; Kato J; Kato N
    Am J Physiol Cell Physiol; 2024 Oct; 327(4):C1150-C1161. PubMed ID: 39250819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib inhibits the growth of lenvatinib-resistant hepatoma cells restoring FTCD expression.
    Fujita K; Yamada M; Morishita A; Ono M; Himoto T; Kobara H; Masaki T
    Biochem Pharmacol; 2024 Aug; 226():116321. PubMed ID: 38815631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib.
    Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J
    Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
    Hosseini MM; Kurtz SE; Abdelhamed S; Mahmood S; Davare MA; Kaempf A; Elferich J; McDermott JE; Liu T; Payne SH; Shinde U; Rodland KD; Mori M; Druker BJ; Singer JW; Agarwal A
    Leukemia; 2018 Nov; 32(11):2374-2387. PubMed ID: 29743719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GOLM1 dictates acquired Lenvatinib resistance by a GOLM1-CSN5 positive feedback loop upon EGFR signaling activation in hepatocellular carcinoma.
    Xie P; Wu M; Wang H; Zhang B; Zhang Z; Yan J; Yu M; Yu Q; Zhao Y; Huang D; Xu M; Xu W; Li H; Xu Y; Xiao Y; Guo L
    Oncogene; 2024 Oct; 43(42):3108-3120. PubMed ID: 39251847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
    Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
    Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.